All Stories

  1. Novel Points of Attack for Targeted Cancer Therapy

    Article • Basic & Clinical Pharmacology & Toxicology, October 2014, Wiley

    Dr Agnete Svendsen Tenfjord Engelsen

  2. Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

    Article • Acta Neuropathologica, August 2011, Springer Science + Business Media

    Dr Agnete Svendsen Tenfjord Engelsen

  3. Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma

    Article • PLoS ONE, July 2011, PLOS

    Dr Agnete Svendsen Tenfjord Engelsen